SCHEMBL1019968

SCHEMBL1019968

O=C(Nc1ccccc1)Nc1ccc(C(=O)O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 3/20 0.74
SMN1; SMN2 Q16637 2/20 0.74
TP53 P04637 1/20 0.74
EPHX1 P07099 1/20 0.74
TSHR P16473 1/20 0.74
CDK9 P50750 1/20 0.74
CLK4 Q9HAZ1 1/20 0.74
TAAR1 Q96RJ0 3/20 0.71
NPC1 O15118 2/20 0.71
RAB9A P51151 2/20 0.71
MAPT P10636 1/20 0.71
ALDH1A1 P00352 1/20 0.71
CASP3 P42574 1/20 0.69
SENP7 Q9BQF6 1/20 0.69
SIRT1 Q96EB6 1/20 0.68
MAOA P21397 2/20 0.67
MAOB P27338 2/20 0.67
POLB P06746 1/20 0.65
NR1H4 Q96RI1 1/20 0.65
KMT2A Q03164 3/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4745756 0.93 EPHX2 (0.71) EPHX2SMN1; SMN2TP53EPHX1TSHR
SCHEMBL19501650 0.92 SIRT1 (0.82) EPHX2SMN1; SMN2TP53EPHX1TSHR
SCHEMBL11059378 0.89 SMN1; SMN2 (0.94) EPHX2SMN1; SMN2TP53EPHX1TSHR
Urea SCHEMBL4746502 0.87 EPHX2 (0.65) EPHX2SMN1; SMN2TP53EPHX1TSHR
Diphenylurea SCHEMBL133103 0.86 SMN1; SMN2 (1.00) EPHX2SMN1; SMN2TP53EPHX1TSHR
SCHEMBL7254876 0.85 FAAH (0.70) EPHX2SMN1; SMN2EPHX1MAPTPOLB
SCHEMBL12010921 0.85 SIRT1 (0.92) EPHX2SMN1; SMN2TP53EPHX1TSHR
SCHEMBL17831070 0.85 RAB9A (0.71) EPHX2SMN1; SMN2TP53EPHX1TSHR
SCHEMBL12113118 0.85 SIRT1 (0.92) EPHX2SMN1; SMN2TP53EPHX1TSHR
SCHEMBL19501531 0.84 SIRT1 (0.64) EPHX2SMN1; SMN2TP53EPHX1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190144399-A1 NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF NANJING SHIQI PHARMACEUTICAL CO. LTD. (CN) 2019-05-16 US disclosed
US-8314091-B2 N-benzyl,N'-arylcarbonylpiperazine derivatives MSD OSS B.V. (NL) 2012-11-20 US disclosed
EP-2190827-B1 N-BENZYL-N'-ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS ORGANON NV (NL) 2011-01-12 EP disclosed
EP-2190827-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. Organon (NL) 2010-06-02 EP disclosed
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES N.V. ORGANON AND PHARMACOPEIA, INC. 2009-10-22 US disclosed
WO-2009024550-A1 N-BENZYL, N' -ARYLCARBONYLPIPERAZINE DERIVATIVES AS LXR MODULATORS N.V. ORGANON (NL) 2009-02-26 WO disclosed
EP-1158985-A4 OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS BAYER PHARMACEUTICALS CORP (US) 2008-03-12 EP disclosed
EP-1158985-A1 OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS Bayer Corporation (US) 2001-12-05 EP disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 EP disclosed
WO-2000041698-A1 φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS BAYER CORPORATION (US) 2000-07-20 WO disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 WO disclosed
US-4001218-A BACTERICIDES BAYER AKTIENGESELLSCHAFT (DT) 1977-01-04 US disclosed
US-3982011-A ANTIBIOTICS, ANIMAL GROWTH PROMOTERS BAYER AKTIENGESELLSCHAFT (DT) 1976-09-21 US disclosed
US-3931153-A BACTERICIDE BAYER AKTIENGESELLSCHAFT (DT) 1976-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190144399-A1 NOVEL 2,4,6-TRISUBSTITUTED S-TRIAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF VIM, HASPIN, WASF2 EPHX2 3935/4885SMN1; SMN2 4678/4885TP53 70/4885
US-20090264416-A1 N-BENZYL,N'-ARYLCARBONYLPIPERAZINE DERIVATIVES NPC1L1, NPC1, ABCB11 EPHX2 1236/4885SMN1; SMN2 4452/4885TP53 4778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.